TY - JOUR T1 - Ceftolozane/tazobactam for the treatment of Pseudomonas aeruginosa infections: A multicenter case series analysis JO - Enfermedades Infecciosas y Microbiología Clínica T2 - AU - Leitão,Inês Leonor AU - Mimoso Santos,Carla AU - André,Paulo AU - Lino,Sara AU - Lemos,Marcos AU - Froes,Filipe SN - 0213005X M3 - 10.1016/j.eimc.2021.12.008 DO - 10.1016/j.eimc.2021.12.008 UR - https://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-articulo-ceftolozane-tazobactam-for-treatment-pseudomonas-aeruginosa-S0213005X22000064 AB - IntroductionPseudomonas aeruginosa displays resistance to several available antibiotics. Infections caused by this pathogen are associated with a high mortality, morbidity, and considerable healthcare resource utilization and costs. This study was aimed at describing the use of ceftolozane/tazobactam (C/T) for the treatment of patients with P. aeruginosa infections. MethodsCase series analysis of hospitalized patients treated with C/T for P. aeruginosa infections in five public Portuguese hospitals. Patients presenting with infections caused by this pathogen and receiving C/T for at least 72h during hospitalization were eligible. ResultsSixty-four hospitalized patients with P. aeruginosa infections treated with C/T were evaluated between December 2016 and July 2019. Most patients were aged between 60 and 79 years (53.9%). Patients presented a total of 68 P. aeruginosa infections, with respiratory infections being the most common (28.1%, 18 out of 64). Most P. aeruginosa strains (85.9%, 55 out of 64) were extensively drug-resistant (XDR). C/T was mostly used as targeted therapy (98.4%, 63 out of 64 patients) and as monotherapy (72.7%, 47 out of 64 patients). Combination therapy was used in 47.4% (9 out of 19) of patients with bacteriemia. Most patients had successful microbiological (79.2%, 42 out of 53) and clinical (78.7%, 48 out of 61) outcomes. All-cause in-hospital mortality rate was 34.4%. ConclusionThe present case series contributes to the body of evidence suggesting that C/T is an effective and safe option for treating P. aeruginosa infections, namely those caused by XDR strains, both when used as mono- or combination therapy. ER -